After 10 years, a whistleblower is vindicated. Here’s why he kept going.

Stefan Franzen
Stefan Franzen

Stefan Franzen doesn’t give up. Ten years ago, he began to suspect the data behind his colleagues’ research about using RNA to make palladium nanoparticles, a potentially valuable tool that ended up as a Science paper. Recently, the National Science Foundation (NSF) decided to cut off funding for Bruce Eaton and Dan Feldheim — currently at the University of Colorado at Boulder — and last week, Science retracted the paper. We talked to Franzen, based at North Carolina State University (NCSU), about his decade-long efforts, and how it feels to be finally vindicated.

Retraction Watch: How did you first begin to suspect the findings by Eaton and Feldheim?

Stefan Franzen: Starting in early 2005, I was collaborating with Drs. Eaton and Feldheim at NCSU, thanks to two joint grants from the W.M. Keck Foundation and NSF. During a group meeting in December of 2005, a graduate student showed electron microscopy data that were inconsistent with the assignment of the particles as palladium. Over time, we kept producing more data that called their findings into question; in April 2006, a postdoc showed that the hexagonal particles could be obtained without RNA. By then, I could see that there was a significant discrepancy between what was written in the articles and what was done and observed in the laboratory.

RW: How did you report your concerns?

Continue reading After 10 years, a whistleblower is vindicated. Here’s why he kept going.

Sparks fly in Finland over misconduct investigation

JEMResearchers in Finland are criticizing an investigation by VTT Technical Research Centre into one of its scientists.

The investigation followed allegations about the VTT’s plasma and serum metabolomics (QBIX) group, previously led by Matej Orešič (who is now based at the Steno Diabetes Center in Gentofte, Denmark) and Tuulia Hyötyläinen. Kai Simons, who conducted an earlier investigation of the group, and the Chancellor Emeritus at the University of Helsinki, have criticized VTT, saying it cut corners in its investigation.

VTT found no evidence of data tampering or falsification in a 2008 paper co-authored by Orešič in the Journal of Experimental Medicine, but said the paper — which has not been corrected or retracted — included some “exaggerated conclusions.” In turn, Orešič and Hyötyläinen filed a complaint for “an alleged violation of good scientific practice” by Simons during the initial investigation. Continue reading Sparks fly in Finland over misconduct investigation

Chemist sues University of Texas (again) to keep PhD

Screen Shot 2016-02-08 at 4.34.25 PMA chemist is suing the University of Texas a second time in an effort to keep the PhD she earned in 2008.

In 2014, school officials revoked Suvi Orr‘s degree after finding it was based, in part, on falsified data. Some of the data were also included in a paper in Organic Letters that was retracted in 2011 after some steps in the chemical synthesis the authors described were not reproducible. Orr, currently working at Pfizer, sued UT, and the school reinstated her degree.

Now, the school is trying to remove it again, according to the lawsuit, filed last week. The lawsuit says the school has scheduled a “hearing” on March 4, during which three undergraduate students and two faculty members will deliberate — “none of whom are qualified to evaluate the scientific evidence being used against S.O.,” the suit says.

Orr has requested a temporary injunction to halt the proceedings, and a hearing has been scheduled for next week, according to the Austin-American Statesman.

The suit argues the school does not have the right to strip Orr’s degree from her: Continue reading Chemist sues University of Texas (again) to keep PhD

Should there be “data authors?” Q&A with NEJM editor Jeffrey Drazen

Jeffrey Drazen ©2011 Jon Chomitz Photography 3 Prescott street, Somerville, MA 02143 www.chomitz.com jon@chomitz.com 617.625.6789
Jeffrey Drazen ©2011 Jon Chomitz Photography

Would designating a set of authors as responsible for data production – separate from those who conduct the analysis – help boost the reliability of papers? That’s a question raised by the editor of the New England Journal of Medicine, Jeffrey Drazen. Along with many other editors of top medical journals, Drazen recently signed a proposal by the International Committee of Medical Journal Editors to require authors of clinical trials to share anonymous patient data within six months of publication. He talked to us about another way to make trials more robust: Create “data authors.”

Retraction Watch: What has been the reaction so far to ICMJE’s data sharing proposal? Continue reading Should there be “data authors?” Q&A with NEJM editor Jeffrey Drazen

Labor pains study brought into this world twice

YJPAI_v16_i6_COVER.inddA group of authors published two articles about one study on pain during childbirth, so one journal is retracting it.

This may seem like a standard case of salami slicing — but this one comes with a nearly 600-word commentary co-authored by the editors of the two journals in question.

The commentary lays out — in a refreshingly transparent way — exactly why the journals came to a joint decision to retract one of the papers:

Continue reading Labor pains study brought into this world twice

Authors used wrong dataset in study on shock therapy, exercise in depression

J psych resA psychiatric journal has pulled a 2014 paper that found electroconvulsive therapy and exercise helped people with depression, after the authors determined they had mistakenly analyzed the wrong data.

According to the retraction notice from the Journal of Psychiatric Research, the researchers had “erroneously analyzed” data from a previous study they had published the year before.

Here’s more from the note for “Electroconvulsive therapy and aerobic exercise training increased BDNF and ameliorated depressive symptoms in patients suffering from treatment-resistant major depressive disorder:” Continue reading Authors used wrong dataset in study on shock therapy, exercise in depression

2014 ORI finding results in retraction of cancer paper with manipulated images

Mol Can TherA paper flagged in an Office of Research Integrity notice more than one year ago has finally been retracted. According to the notice, the paper includes images manipulated by author H. Rosie Xing, a former University of Chicago cancer researcher.

The main conclusions of the paper are affected by the ORI finding, according to the retraction note from Molecular Cancer Therapeutics. But otherwise, the note contains information that was available in the ORI finding, published in December 2014.

Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment” has been cited seven times, according to Thomson Scientific’s Web of Knowledge — twice since the ORI finding came out.

The retraction note explains which images were affected by the manipulation:

Continue reading 2014 ORI finding results in retraction of cancer paper with manipulated images

Investigation prompts 5th retraction for cancer researcher for “unresolvable concerns”

3.coverAn investigation at the University of New South Wales in Australia has led to a fifth retraction for a cancer researcher long accused of misconduct, due to “unresolvable concerns” with some images.

As we reported in December, UNSW cleared Levon Khachigian of misconduct, concluding that his previous issues stemmed from “genuine error or honest oversight.” Now, Circulation Research is retracting one of his papers after an investigation commissioned by UNSW was unable to find electronic records for two similar images from a 2009 paper, nor records of the images in original lab books.

Again, the retraction note affirms that this is not a sign of misconduct:

UNSW has not attributed any instance of research misconduct or responsibility for the unavailability of the original data to Professor Khachigian or to any of the authors of the publication.

Here’s the retraction note in full for “Angiotensin II-Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement:” Continue reading Investigation prompts 5th retraction for cancer researcher for “unresolvable concerns”

After hesitating, Science retracts chemistry paper against authors’ wishes

F1.mediumToday, Science has retracted a 2004 paper that’s been under scrutiny for years, despite the authors’ objections.

This paper has a long backstory: Recently, a report from the National Science Foundation’s Office of Inspector General surfaced that announced the agency had cut off the authors from funding. Last month, editor Marcia McNutt told us that the journal planned to retract the paper as soon as possible. Then, on January 21st, “just as we were going to press with the retraction,” said McNutt, the authors submitted a correction, which Science wanted to take some time to consider.

Now, the paper has a retraction note, against the wishes of authors Bruce Eaton and Dan Feldheim, currently at the University of Colorado.

Here it is the retraction note:

Continue reading After hesitating, Science retracts chemistry paper against authors’ wishes

Data irregularities force author to retract three solar cell papers

no spine minimum. full size. Editor: Jon JEM: Esther RTP: Bryan Nolte TOC image

An engineer has retracted three papers on a method for making nanoscale materials that are useful in solar cells.

The papers, all published in ACS Applied Materials & Interfaces, contain irregularities in data, and one includes images “which have been published elsewhere and identified with different samples,” according to the note.

The first author on all three papers is Khalid Mahmood, who — according to the bio from a talk he gave last year on efficient solar cells — is currently a postdoc at King Abdullah University of Science and Technology in Saudi Arabia. He did the work in the retracted papers while a student at the Korea Advanced Institute of Science and Technology, where, according to the bio, he completed his PhD in two years.

Here’s the retraction note for the first paper (which also contains a typo in the title — “electrospay”)

Continue reading Data irregularities force author to retract three solar cell papers